hydroxychloroquine plus macrolides - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.64 [0.18, 2.24]< 10%1 study (1/-)75.7 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.99 [0.57, 1.72]< 10%1 study (1/-)51.4 %some concernnot evaluable moderateimportant-

safety endpoints 00

arrhythmia 2.24 [0.23, 21.69]< 10%1 study (1/-)24.5 %some concernnot evaluable moderatenon important-
long QT 9.79 [1.27, 75.50]< 10%1 study (1/-)1.5 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.